Pentagon Orders Testosterone Screening for Troops

What Happened

Defense Secretary Pete Hegseth announced that service members age 30 and older will receive annual screening for testosterone deficiency as part of their periodic health assessment. Service members under 30 may volunteer for testing. Hegseth said testosterone replacement therapy would be voluntary for people for whom it is recommended.

Fact check: The announcement establishes screening, not automatic treatment. The Pentagon has not released additional implementation guidance, according to reporting by the Associated Press and CBS News. That leaves open practical questions about diagnostic criteria, referrals, records, costs, and the number of service members who might be affected.

Background

Testosterone is a hormone with important roles in sexual development, bone health, muscle mass, and other functions. In men, levels can decline with age, but symptoms associated with low testosterone can overlap with many other conditions and with normal aging. The Food and Drug Administration says approved testosterone products are for men with low testosterone tied to an associated medical condition. The FDA also retains language limiting use for age-related hypogonadism.

The Endocrine Society says a diagnosis of hypogonadism should be based on symptoms and consistently low results, including repeat early-morning fasting tests. It recommends against routine screening of the general population for hypogonadism. The military program is not the same as a civilian population-wide policy, but that guidance is relevant context for the debate over broad screening.

Evidence, Benefits, and Risks

Hegseth described the goal as helping troops remain strong, resilient, and capable. Military training and stress can affect hormone levels, and supporters may see screening as a way to identify an overlooked health issue. The announcement also emphasizes that treatment would be a choice.

Medical evidence does not support treating a single test result as a diagnosis. Studies have found some benefits from treatment for men with confirmed deficiency, but experts disagree about wider use for nonspecific symptoms such as fatigue or lower energy. The FDA says a large trial did not find increased major cardiovascular events among men using testosterone for hypogonadism, while blood-pressure studies led the agency to require product-specific blood-pressure warnings. Fertility plans and prostate-related risks are among the issues clinicians may consider when discussing treatment.

Questions About Women, Cost, and Implementation

The announcement referred broadly to troops, but the Pentagon did not answer questions about whether female service members would be evaluated for hormone-related care, including estrogen-based therapy during perimenopause. That uncertainty has prompted questions about whether the policy will be applied equally and what clinical standard will be used for different patients.

No public cost estimate, service-wide clinical protocol, or timetable for implementation beyond the announcement has been released. Those details will help determine whether the policy is mainly a screening addition to existing checkups or a larger expansion of testing and treatment.

What Different Sides Are Saying

Supporters can frame the policy as a readiness and long-term health measure, especially for troops whose training or operational demands may affect hormone levels. They may also argue that voluntary treatment protects personal choice.

Critics and some medical experts caution that broad screening can lead to overdiagnosis or treatment without a clear medical need. They point to guidance calling for symptoms and repeated testing, as well as the need to discuss blood pressure, fertility, and other risks. Others focus on fairness, asking whether hormone-related care for women will receive the same attention and access.

Discussion Questions

What should count as evidence that a screening program improves readiness?
How should the military distinguish screening from diagnosis?
Why might repeated testing matter for hormone levels?
What benefits and risks should service members hear about before choosing treatment?
Should the policy apply the same way to all service members?
How should military health policy address hormone-related care for women?
What information would you want about the program’s cost?
When should a health policy focus on long-term wellness rather than immediate readiness?
What would fair access to follow-up care look like?
If you were reviewing the policy after one year, what results would you examine?

Pentagon Orders Testosterone Screening for Troops 30 and Older